Rapiscan 400 microgram solution for injection

DRUG4 trials

Sponsors

Synektik S.A., GE Healthcare Limited, Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer

Conditions

Coronary Artery DiseaseCoronary artery chronic total occlusionKawasaki diseasePatients who need to undergo a clinically indicated pharmacologic stress perfusion CMR test and who are considered fit for a pharmacological stress perfusion CMR by the investigator. The pharmacologic stress perfusion CMR may be performed in patients for further evaluation of cardiovascular conditions or diseasesand post-cardiac surgery / transplantationbut not limited tocongenital coronary abnormalitiescongenital heart diseases

Phase 1

An Open-label, Single-dose, Safety and Pharmacokinetic Study of Regadenoson in Paediatric Patients

Not yet recruitingCTIS2024-515244-22-00

GE Healthcare Limitedand post-cardiac surgery / transplantation, but not limited to, congenital coronary abnormalities +5

Target: 3Updated: 2025-11-12

Phase 2

Absolute quantification of myocardial blood flow in human subjects with SYN2 dynamic PET imaging

RecruitingCTIS2023-507520-23-00

Synektik S.A.Coronary Artery Disease

Start: 2024-09-03Target: 30Updated: 2025-01-27

Phase 3

A Phase III Prospective, Multicenter, Open-label Study to Assess Diagnostic Efficacy of a Novel 18F-labelled Tracer, SYN2, for Positron Emission Tomography in Subjects with Suspected Coronary Artery Disease

RecruitingCTIS2023-506971-89-00

Synektik S.A.Coronary Artery Disease

Start: 2024-01-25Target: 220Updated: 2026-01-07

Phase 4

Evaluation of patients with total coronary occlusions with multimodality image.

Not yet recruitingCTIS2024-519979-26-00

Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I SunyerCoronary artery chronic total occlusion

Target: 78Updated: 2025-01-10